Improvements in model performance upon addition of a second biomarker were small in magnitude.
CONCLUSIONS:
Biomarkers can add prognostic information to the GRACE score even in the current era of high-sensitivity cardiac troponin assays. The incremental information offered by individual biomarkers varies considerably, however.
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Guidelines for the management of non-ST-elevation acute coronary syndrome (NSTE-ACS) 6 emphasize the importance of risk stratification to match the intensity of therapy with an individual patient's risk (1, 2 ). The guidelines recommend a standardized approach that uses scoring systems such as the Global Registry of Acute Coronary Events (GRACE) score to calculate risk and guide management decisions (1, 2 ). Because scores reflect only some disease dimensions related to outcome in NSTE-ACS, biomarkers addressing separate aspects of NSTE-ACS pathophysiology may provide additional information (3 ) .
With an increasing number of studies relating individual biomarkers to prognosis in NSTE-ACS, there is a growing uncertainty about the differential performance of these biomarkers (4 -17 ) . Moreover, only a few studies have examined the incremental prognostic value of biomarkers when used in combination with risk scores such as GRACE, which already incorporates information from biomarkers of myocardial damage and renal function (16 -21 ) . Differences in study design preclude comparisons of biomarker performances based on these studies.
Recently, cardiac troponin assays with increased analytic performance have been introduced into clinical practice (22 ) . With the use of these assays, patients presenting with troponin elevations just above the 99th percentile of a reference population, which could not be detected reliably with previous less-sensitive assays, were shown to be at increased risk of death and ischemic events (23, 24 ) . It is not known if biomarkers can enhance risk stratification on top of GRACE and a high-sensitivity cardiac troponin measurement.
Materials and Methods

STUDY POPULATION AND FOLLOW-UP
The study was approved by the institutional committees on human research at both institutions. The study included 1146 consecutive patients with NSTE-ACS who were selected retrospectively from a cohort of 2445 patients with nontraumatic chest pain suggestive of myocardial ischemia who were admitted to our cardiology departments in Hannover or Heidelberg. Serum samples were obtained on admission from all 2445 patients. Among these patients, 1146 had NSTE-ACS (NSTEMI or unstable angina pectoris), 710 STEMI, 279 other cardiac disease, and 310 noncardiac chest pain. All patients provided written informed consent within 24 h after admission. Refusal to provide consent was the only exclusion criterion. All treatment decisions were left to the discretion of the attending cardiologists.
According to the Universal Definition of Myocardial Infarction, NSTEMI was diagnosed in patients showing a rise and/or fall of cardiac troponin T (cTnT) above the diagnostic threshold for MI during serial testing for at least 12 h. Patients were diagnosed with unstable angina if they had cTnT concentrations consistently below the diagnostic threshold for MI or persistent cTnT elevations (no rise and/or fall) during serial testing for at least 12 h. To make the diagnosis of unstable angina, we also required that these patients had signs of myocardial ischemia on electrocardiogram, or a history of coronary artery disease, or at least 1 stenosis of Ն50% in a major coronary artery on angiography. Patients were recruited between August 2007 and August 2011. Initially, cTnT was measured with the fourth generation Roche Diagnostics assay with 30 ng/L as diagnostic threshold for MI, a concentration that this assay can measure with Ͻ10% total imprecision (25 ) (495 patients). During the course of the study, the fourth generation assay was replaced by the Roche Diagnostics high sensitivity cTnT (hs-cTnT) assay in both institutions, and 14 ng/L was used as the diagnostic threshold for MI, the 99th percentile of a reference population which this assay can measure with Ͻ10% total imprecision (26 ) (651 patients). Therefore, in patients with a diagnosis of unstable angina based on serial measurements with the fourth generation assay, NSTEMI would have been diagnosed with the hs-cTnT assay (27 ) . Between 2009 and 2011, 6 lots of the hs-cTnT assay displayed a downward shift at low concentrations of the measurement interval (28 ) . Thus, in some patients with a diagnosis of unstable angina determined with the use of these lots, NSTEMI would have been diagnosed with a well-standardized hs-cTnT assay (28 ) . Results from these measurements were used for diagnostic purposes only and were not used in the calculation of the GRACE score or to assess the prognostic value of hs-cTnT. Please note that the GRACE score considers all NSTE-ACS patients and does not distinguish between unstable angina and NSTEMI.
Deaths and nonfatal MIs were recorded from admission to 6 months. Follow-up was accomplished in all patients by telephone contact or questionnaire at 6 months. When a patient, spouse, or primary care physician reported another hospital admission for a cardiovascular reason, hospital discharge letters (or final reports on deceased patients) were obtained and searched for a diagnosis of a fatal cardiac event or nonfatal MI (STEMI or NSTEMI). Cardiac death was defined as death during hospitalization with MI, death from progressive heart failure, death from documented cardiac arrhythmias, or sudden or unwitnessed death not related to accidents, suicide, terminal cancer, or other ominous diagnoses. We provide this information on the mode of death and type of MI to characterize our patient population. The GRACE score however, predicts all-cause mortality and all nonfatal MIs. All end points were adjudicated by 2 cardiologists. In rare cases of disagreement, a third cardiologist was consulted to reach consensus.
BIOMARKER ASSAYS
Serum samples were obtained by venipuncture on admission and stored at Ϫ70°C. Samples were thawed once to measure the following biomarkers. cTnT was measured with the electrochemiluminescence hs-cTnT assay from Roche Diagnostics. Recently, the company reported a downward shift at low concentrations of the measurement interval in 6 lots of the assay, including lot 163704, which we had used for our measurements. This shift was not due to a change in reagent formulation but to the standardization against the master lot (28 ). Applying an adjusted standardization procedure (28 ) , Roche Diagnostics recalculated the hs-cTnT values using the calibration data and original signal counts that we had obtained in our patients (see Fig. 1 
CALCULATION OF THE GRACE SCORE
The GRACE score is derived from 8 variables that are available on admission (age, heart rate, systolic blood pressure, serum creatinine concentration, Killip class, cardiac arrest, presence of ST-segment deviation, and increased cardiac marker) (30 ) . Values for these variables were entered into the GRACE risk calculator (www.outcomes-umassmed.org/grace/) to obtain estimates of the cumulative risks of all-cause mortality and all-cause mortality or nonfatal MI in the period from admission to 6 months. The combined end point of all-cause mortality or nonfatal MI was the prespecified primary end point of the study. All-cause mortality was analyzed as a secondary end point. An hs-cTnT concentration Ͼ14 ng/L was used to define increased cardiac marker in the score. Serum creatinine concentrations were measured at the local study sites.
STATISTICAL ANALYSIS
Categorical variables are reported as numbers and percentages, continuous variables as medians with interquartile range (IQR). To limit the influence of extreme observations, all biomarker values were natural logtransformed. A total of 233 patients had a copeptin concentration below the limit of detection (LOD) (4.8 pmol/L); 22 patients had an FGF23 concentration below the LOD (3 ng/L); for these samples we imputed the midpoint between zero and the LOD (31 ) . Eight patients had a cystatin C concentration below the instrument minimal reading of 0.4 mg/L; for these samples we imputed a concentration of 0.2 mg/L. Four patients had an hs-cTnT concentration below the limit of the blank (3 ng/L); for these samples we imputed a concentration of 1.5 ng/L. The probabilities derived from the GRACE score were transformed into their linear predictor form. Continuous variables were compared with the Mann-Whitney test and categorical variables with the 2 test. The Pearson correlation coefficient was calculated to assess the correlations between individual biomarkers and GRACE score probabilities. We examined the associations of individual biomarkers with outcome events using logistic regression models. Natural log-transformed biomarker distributions were standardized to a mean of zero and standard deviation (SD) of 1 to facilitate comparison of effects sizes between biomarkers. We determined the area under the ROC curve (AUC) to assess the discriminatory performance of the GRACE score and individual biomarkers. We assessed the incremental prognostic value of biomarkers when added to the GRACE score by the likelihood ratio test (32 ) . We used 3 complementary measures of discrimination improvement to assess the magnitude of the increase in model performance when individual biomarkers were added to GRACE: change in AUC (⌬AUC), integrated discrimination improvement (IDI), and continuous and categorical net reclassification improvement (NRI) (33 ) . To get a sense of clinical usefulness, we calculated the NRI(Ͼ0.02), which considers 2% as the minimum threshold for a meaningful change in predicted risk. Moreover, 2 categorical NRIs were applied with prespecified risk thresholds of 6% and 14%, chosen in accord with a previous study (17 ) , or 5% and 12%, chosen in accord with the observed event rate in the present study. Categorical NRIs define upward and downward reclassification only if predicted risks move from one category to another. Since the number of biomarkers added to GRACE remained small (maximum of 2), the degree of overoptimism was likely to be small (34 ) . Still, we reran the ⌬AUC and IDI analyses using bootstrap internal validation and confirmed our results. Analyses were performed using SPSS statistics version 19 and SAS 9.3.
Results
PATIENT POPULATION, GRACE SCORE, AND BIOMARKER
CONCENTRATIONS
Baseline characteristics, GRACE score variables, and biomarker concentrations are reported in Table 1 . Six months after admission, 78 patients (6.8%) had reached the combined end point of death (41 cardiac, 12 noncardiac deaths) or nonfatal MI (3 STEMI, 22 NSTEMI). Online Supplemental Fig. 2 shows the timing of events. Patients who reached the combined end point presented with higher GRACE score points and higher biomarker concentrations compared with patients who did not (Table 1). The GRACE score was moderately correlated with NT-proBNP (r ϭ 0.59) and GDF-15 (0.58); more modestly with cystatin C (0.48), hs-cTnT (0.45), copeptin (0.43), galectin-3 (0.40), hs-CRP (0.33), and sST2 (0.30); and weakly with FGF23 (0.11) (all P Ͻ 0.001).
DIFFERENTIAL PROGNOSTIC PERFORMANCE OF INDIVIDUAL
BIOMARKERS
Increasing concentrations of all biomarkers were associated with the risk of death or nonfatal MI at 6 months ( Fig. 1) . Based on the odds ratio (OR) per 1 SD increase in the natural log-transformed biomarker concentration, NT-proBNP (OR 2.4) and GDF-15 (OR 2.4) showed the strongest associations to outcome (Fig. 1) . The GRACE score and all biomarkers provided significant discriminatory information, as evidenced by their AUC with corresponding 95% CIs that were nonover- lapping with the nondiscriminatory value of 0.5 (Table  2) ; the GRACE score alone had an AUC of 0.749. GDF-15 (AUC 0.771) and NT-proBNP (AUC 0.745) emerged as the biomarkers with the greatest discriminatory strength (Table 2) .
INCREMENTAL PROGNOSTIC INFORMATION PROVIDED BY BIOMARKERS WHEN ADDED TO GRACE
All biomarkers offered statistically significant improvements in model performance when added to GRACE (likelihood ratio test in Table 3 ). The magnitude of model improvement varied considerably, how- ORs for 6-month all-cause mortality or nonfatal MI per 1 SD increase in the natural log-transformed biomarker (ln biomarker) levels. ever: the ⌬AUC ranged from 0.003 to 0.039, the IDI from 0.009 to 0.049, and the category-free NRI(Ͼ0) from 0.237 to 0.554 (Table 3) . To illustrate biomarker performance across these statistical metrics, we ranked biomarkers according to their performance relative to the other markers; for each metric, the best marker was attributed rank 1, the worst marker rank 9 ( Table 3) . The ranks in the ⌬AUC, IDI, and NRI(Ͼ0) categories were added up to calculate a rank sum. On a scale of 3 to 27 (with higher numbers indicating worse performance), GDF-15 achieved a rank sum of 3 because it ranked in first place in all 3 categories. The second best marker was NT-proBNP, with a rank sum of 9 (Table 3) .
In a sensitivity analysis, we examined the incremental prognostic value of our 9 biomarkers only in patients who were included after the hs-cTnT assay had been introduced in our institutions (n ϭ 651). GDF-15 and NT-proBNP emerged again as the 2 most promising biomarkers adding prognostic information to GRACE [GDF-15, likelihood ratio test P ϭ 0.003; ⌬AUC 0.028; IDI 0.030; NRI(Ͼ0) 0.484; NT-proBNP, P ϭ 0.012; ⌬AUC 0.024; IDI 0.016; NRI(Ͼ0) 0.467].
When we assessed the incremental prognostic information provided by our biomarkers upon addition to a model containing the individual GRACE variables (not combined into a score), the magnitude of the incremental prognostic information remained similar to that shown in Table 3 ; GDF-15 emerged again as the most promising biomarker.
RECLASSIFICATION ACROSS PREDEFINED RISK THRESHOLDS
The category-free NRI(Ͼ0) reflects any reclassification in the correct direction regardless of its magnitude. Potential for clinical benefit achieved when GDF-15 or NT-proBNP were added to GRACE was therefore assessed by calculating the NRI(Ͼ0.02), which considers 2% as minimum threshold for a change in predicted risk. Along the same line, we calculated a category-based NRI to assess the ability of GDF-15 and NT-proBNP to reclassify patients across predefined risk thresholds classifying patients as low (Ͻ6%), intermediate (6%-14%), or high risk (Ͼ14%). Both markers enabled net reclassification across these thresholds: GDF-15, NRI(6/14) 0.187 (95% CI 0.051-0.323); NT-proBNP, 0.154 (0.042-0.267) (see online Supplemental Table 2 ).
Because net reclassification depends on the chosen risk thresholds (33 ) , in sensitivity analysis we defined 5% and 12% as alternative thresholds that were more evenly distributed around the event rate of 6.8%. GDF-15, but not NT-proBNP, enabled net reclassification across these thresholds: GDF-15, NRI(5/12) 0.183 (95% CI 0.052-0.315); NT-proBNP, 0.108 (-0.021-0.237).
INCREMENTAL VALUE BEYOND GRACE AND hs-cTnT
Guidelines recommend that cardiac troponin be measured with a high-sensitivity assay on admission in all NSTE-ACS patients (2 ) . Since GRACE considers the results from this troponin test only as a binary variable, we explored whether GDF-15 or NT-proBNP add prognostic information to a model including GRACE plus hs-cTnT as a continuous variable (because this information is clinically available before any other biomarker is measured). Both markers added statistically significant prognostic information to GRACE plus hscTnT (Table 4 ). The magnitude of the improvement in model performance appeared to be greater for GDF-15 than NT-proBNP (Table 4) .
INCREMENTAL VALUE OF ADDING A SECOND BIOMARKER TO GRACE PLUS GDF-15 OR TO GRACE PLUS NT-proBNP
Based on the ⌬AUC, IDI, and NRI(Ͼ0), GDF-15 and NT-proBNP emerged as the 2 most promising biomarkers adding discriminatory information to GRACE (Table 3) . We therefore explored if any of the other 8 biomarkers provided prognostic information on top of GRACE plus GDF-15 or GRACE plus NT-proBNP. In- creases in model performance were relatively small (see online Supplemental Table 3 ).
SECONDARY ANALYSES
In a posthoc secondary analysis, we assessed the incremental prognostic information provided by biomarkers on top of GRACE concerning the end point of allcause mortality. All biomarkers, except for FGF23, offered statistically significant improvements in model performance (see online Supplemental Table 4 ). NTproBNP and GDF-15 emerged as the most promising markers.
Discussion
This is the first study to compare the incremental prognostic value of biomarkers beyond GRACE and cTnT measured with a high-sensitivity assay in NSTE-ACS. We found that the ability of biomarkers to add prognostic information to GRACE and hs-cTnT varies considerably.
All biomarkers investigated in the present study, except for FGF23, have been linked to adverse outcomes in NSTE-ACS (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) 23 ) . FGF23 is emerging as a prognostic biomarker in chronic kidney disease (35 ) and stable coronary artery disease (36 ) , which prompted us to explore it for the first time in NSTE-ACS. Consistent with these studies, we found all biomarkers to be associated with death or MI and to discriminate patients with or without events ( Fig. 1 and Table 2 ).
The GRACE score alone had an AUC of 0.749 in our patients, thus confirming the score as a valuable tool for risk assessment (30 ) . Three complementary statistical metrics were employed to examine the incremental value of biomarkers beyond GRACE. Reviewing biomarker performances across these metrics, GDF-15 and to a somewhat lesser extent NT-proBNP emerged as the most promising biomarkers (Table 3) . Please note that the rank orders in Table 3 are meant to illustrate biomarker performances relative to the other markers across the 3 statistical metrics. Although these ranks help to identify promising biomarkers and less promising markers as a basis for future studies, it is not our intention to ascribe statistical properties to these ranks (i.e., it is not possible to conclude on the basis of its rank that one marker is significantly better than another marker).
Emphasizing the potential of GDF-15 and NTproBNP to add information to what is clinically available, we found that GDF-15 and to a somewhat lesser extent NT-proBNP also added discriminatory information to GRACE when hs-cTnT was considered as an additional continuous variable (Table 4) . Addition of a second biomarker on top of GRACE plus GDF-15 or GRACE plus NT-proBNP added little discriminatory information, perhaps because the score already includes information from biomarkers of renal function and myocardial damage.
Notably, some biomarkers performed differently across the 3 statistical metrics. Biomarker performance across these metrics depends on the strength of the baseline model (GRACE score) and the effect size of the candidate marker and its correlation with GRACE. The ⌬AUC heavily depends on the strength of the baseline model, which is true to a lesser degree for the IDI. On the other hand, the NRI(Ͼ0) depends mainly on the effect size of the candidate marker and its correlation with GRACE (33 ) . Moreover, the NRI(Ͼ0) tends to favor markers that offer smaller improvements for many people, whereas the IDI picks up large improvements for few people (33 ) .
The increases in the AUC achieved when individual biomarkers were added to the GRACE score ranged from 0.003-0.039, which is relatively modest. However, even variables with strong effect sizes lead to only small numerical increases in the AUC when added to a strong baseline model such as GRACE (33 ) . Indeed, employing the NRI(Ͼ0) as a metric not as easily influenced by the strength of the baseline model, we conclude that GDF-15 offers an increment consistent with a medium-to-strong effect size and NT-proBNP an increment consistent with a medium effect size (33 ) . The strength of GDF-15's impact was confirmed by its impressive IDI of 0.049 (with an event rate of 0.068, GDF-15 separated events from nonevents by a further 0.049).
We are not aware of a previous study comparing the incremental prognostic value of multiple biomarkers beyond a validated risk score such as GRACE and a high-sensitivity cardiac troponin. Some previous studies have examined the incremental prognostic value of individual candidate biomarkers beyond GRACE, but results were heterogeneous (16 -21 ) . Differences in study design (some studies including STEMI), timing of blood sampling (up to 72 h after admission), end points (some studies including heart failure and revascularization end points), and length of follow-up (between 30 days and 1 year) preclude comparisons of biomarker performances based on these studies (16 -21 ) . We focused on NSTE-ACS because risk stratification guides management decisions in this setting (1, 2 ). We created optimal conditions for the GRACE score to predict outcome by utilizing the follow-up interval (admission to 6 months) and the end point (all-cause mortality or nonfatal MI) for which the score was developed. Moreover, we incorporated results from hscTnT testing in the score to reflect the use of highsensitivity troponin assays in current clinical practice. Thus, our study is the first to provide a comparative analysis of the incremental value of biomarkers in the current clinical environment. Unlike many previous studies, our study was not focused on statistical significance but assessed the magnitude of model improvement achieved by individual biomarkers. In fact, all our biomarkers added statistically significant prognostic information, but the incremental prognostic value of individual markers differed widely. Thus, we identified strong biomarker candidates for future studies on biomarker strategies in NSTE-ACS.
The change in the cTnT assay used for diagnostic purposes from the fourth generation to the highsensitivity assay during the study is a limitation because it may have resulted in patients with small NSTEMIs not being included in our cohort and in small NSTEMIs not being diagnosed during follow-up. Importantly, we found our results to be robust when we analyzed only the patients that were included after the hs-cTnT assay had been introduced. Use of hs-cTnT lots with a downward shift at low concentrations for diagnostic purposes on admission and during follow-up will have resulted in very few (if any) missed diagnoses of NSTEMI (28 ) .
In conclusion, our study shows that biomarkers can add prognostic information to GRACE even in the current era of high-sensitivity cardiac troponin assays. Although bootstrap internal validation confirmed our results, the differential performance of the biomarkers investigated here needs to be reexamined in other, preferably larger study populations with more events. More studies are needed to assess whether biomarkerenhanced risk stratification can guide management decisions in NSTE-ACS, as it has previously been suggested for the GRACE score alone (37 ) . As demonstrated here, GDF-15 and NT-proBNP have the potential to reclassify patients in the appropriate directions across risk thresholds, which may trigger changes in treatment decisions in the future. More widespread use of risk scores and prognostic biomarkers in clinical practice will help to match the intensity of therapy with an individual patient's risk and will enable judicious allocation of healthcare resources. 
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